Paladin, Valeant raise stakes in bidding for Afexa

Canada's Afexa Life Sciences has sparked a bidding war. This morning, Paladin Laboratories topped Valeant Pharmaceuticals' 71-cents-a-share bid with an 81-cent offer, but Valeant turned around and raised its bid to 85 cents. Report